Serum and Salivary IgG and IgA Response After COVID-19 Messenger RNA Vaccination
JAMA Network Open · 23.04.2024 · 7 (4) · e248051
DOI: 10.1001/jamanetworkopen.2024.8051 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 23.04.2024. Verfasst von Guy Gorochov und 34 weiteren Autor:innen. Beteiligte Einrichtung: Sorbonne Université, Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d'Immunologie et des Maladies Infectieuses (CIMI), Dé…. Hauptthemen laut MEDLINE: Immunoglobulin G, COVID-19, SARS-CoV-2, Saliva. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance There is still considerable controversy in the literature regarding the capacity of intramuscular messenger RNA (mRNA) vaccination to induce a mucosal immune response.
Objective
To compare serum and salivary IgG and IgA levels among mRNA-vaccinated individuals with or without previous SARS-CoV-2 infection. Design, Setting, and Participants In this cohort study, SARS-CoV-2–naive participants and those with previous infection were consecutively included in the CoviCompare P and CoviCompare M mRNA vaccination trials and followed up to day 180 after vaccination with either the BNT162b2 (Pfizer-BioNTech) vaccine or the mRNA-1273 (Moderna) vaccine at the beginning of the COVID-19 vaccination campaign (from February 19 to June 8, 2021) in France. Data were analyzed from October 25, 2022, to July 13, 2023. Main Outcomes and Measures An ultrasensitive digital enzyme-linked immunosorbent assay was used for the comparison of SARS-CoV-2 spike-specific serum and salivary IgG and IgA levels. Spike-specific secretory IgA level was also quantified at selected times.
Results
A total of 427 individuals were included in 3 groups: participants with SARS-CoV-2 prior to vaccination who received 1 single dose of BNT162b2 (Pfizer-BioNTech) (n = 120) and SARS-CoV-2–naive individuals who received 2 doses of mRNA-1273 (Moderna) (n = 172) or 2 doses of BNT162b2 (Pfizer-BioNTech) (n = 135). The median age was 68 (IQR, 39-75) years, and 228 (53.4%) were men. SARS-CoV-2 spike-specific IgG saliva levels increased after 1 or 2 vaccine injections in individuals with previous infection and SARS-CoV-2–naive individuals. After vaccination, SARS-CoV-2–specific saliva IgA levels, normalized with respect to total IgA levels, were significantly higher in participants with previous infection, as compared with the most responsive mRNA-1273 (Moderna) recipients (median normalized levels, 155 × 10 −5 vs 37 × 10 −5 at day 29; 107 × 10 −5 vs 54 × 10 −5 at day 57; and 104 × 10 −5 vs 70 × 10 −5 at day 180 [ P < .001]). In contrast, compared with day 1, spike-specific IgA levels in the BNT162b2-vaccinated SARS-CoV-2–naive group increased only at day 57 (36 × 10 −5 vs 49 × 10 −5 [ P = .01]). Bona fide multimeric secretory IgA levels were significantly higher in individuals with previous infection compared with SARS-CoV-2–naive individuals after 2 antigenic stimulations (median optical density, 0.36 [IQR, 0.16-0.63] vs 0.16 [IQR, 0.10-0.22]; P < .001). Conclusions and Relevance The findings of this cohort study suggest that mRNA vaccination was associated with mucosal immunity in individuals without prior SARS-CoV-2 infection, but at much lower levels than in previously infected individuals. Further studies are needed to determine the association between specific saliva IgA levels and prevention of infection or transmission.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Sorbonne Université, Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d'Immunologie et des Maladies Infectieuses (CIMI), Département d'Immunologie, Assistance Publique-Hôpitaux de Paris (AP-HP)…
- INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpital Pitié-Salpêtrière, Département de Santé Publique, Unité de Recherche Clinique Paris Sciences et Lettres (PSL)-CFX, Sorbonne Université,…
- Université Paris Cité, INSERM, Centre d'Investigation Clinique (CIC) 1417 Cochin Pasteur, French Clinical Research Infrastructure Network, Innovative Clinical Research Network in Vaccinology, APHP, Hôpital Cochin, Paris…
- INSERM SC10-US019, Villejuif, France.
- AP-HP, Hôpitaux Universitaires Pitié-Salpêtrière-Charles Foix, Unité de Recherche Clinique des Hôpitaux Universitaires Pitié-Salpêtrière, Paris, France.
- AP-HP, Hôpital Cochin, Fédération des Centres de Ressources Biologiques-Plateforme de Ressources Biologiques Centre de Ressources Biologique Cochin, Paris, France.
Zitieren
APA
Gorochov, G., Ropers, J., Launay, O., Dorgham, K., da Mata-Jardin, O., Lebbah, S., Durier, C., Bauer, R., Radenne, A., Desaint, C., Vieillard, L. V., Rekacewicz, C., Lachatre, M., Parfait, B., Batteux, F., Hupé, P., Ninove, L., Lefebvre, M., Conrad, A., …, & Paul, S. (2024). Serum and Salivary IgG and IgA Response After COVID-19 Messenger RNA Vaccination. JAMA Network Open, 7(4), e248051. https://doi.org/10.1001/jamanetworkopen.2024.8051
Vancouver
Gorochov G, Ropers J, Launay O, Dorgham K, da Mata-Jardin O, Lebbah S, et al. Serum and Salivary IgG and IgA Response After COVID-19 Messenger RNA Vaccination. JAMA Network Open. 2024;7(4):e248051. doi:10.1001/jamanetworkopen.2024.8051
BibTeX
@article{Gorochov2024,
author = {Gorochov, Guy and Ropers, Jacques and Launay, Odile and Dorgham, Karim and da Mata-Jardin, Omaira and Lebbah, Said and Durier, Christine and Bauer, Rebecca and Radenne, Anne and Desaint, Corinne and Vieillard, Louis-Victorien and Rekacewicz, Claire and Lachatre, Marie and Parfait, Béatrice and Batteux, Frédéric and Hupé, Philippe and Ninove, Läétitia and Lefebvre, Maeva and Conrad, Anne and Dussol, Bertrand and Maakaroun-Vermesse, Zoha and Melica, Giovanna and Nicolas, Jean-François and Verdon, Renaud and Kiladjian, Jean-Jacques and Loubet, Paul and Schmidt-Mutter, Catherine and Dualé, Christian and Ansart, Séverine and Botelho-Nevers, Elisabeth and Lelièvre, Jean-Daniel and de Lamballerie, Xavier and Kieny, Marie-Paule and Tartour, Eric and Paul, Stéphane},
title = {Serum and Salivary IgG and IgA Response After COVID-19 Messenger RNA Vaccination},
journal = {JAMA Network Open},
year = {2024},
volume = {7},
number = {4},
pages = {e248051},
doi = {10.1001/jamanetworkopen.2024.8051}
}
EUVIMED